Piper Jaffray reiterated an Overweight rating and $407.00 price target on Biogen (NASDAQ: BIIB) following the company's 1Q ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View

Biogen (BIIB) PT Lowered to $311 at RBC CapitalApril 25, 2018 7:43 AM Biogen (BIIB) PT Lowered to $375 at OppenheimerApril 25, 2018 7:15 AM Biogen (BIIB) Tops Q1 EPS by 13c, Miss on RevenuesApril 24, 2018 7:00 AM Biogen Reports Quarterly Revenues of $3.1 BillionApril 24, 2018 6:59 AM Amid drug price worries, earnings to test U.S. pharma, biotech sharesApril 23, 2018 4:49 PM Biogen (BIIB) weekly option implied volatility elevated into Q1April 23, 2018 11:27 AM Nomura/Instinet Reiterates Buy on Biogen (BIIB) Following Announced IONS Collaboration April 23, 2018 8:14 AM Biogen (BIIB) Reports New SPINRAZA (nusinersen) Data at AAN MeetingsApril 23, 2018 7:33 AM New SPINRAZA® (nusinersen) Data Unveiled at AAN Annual Meeting Show Continued Improvement in Motor Function for Broad Age Range and Survival Benefit for InfantsApril 23, 2018 7:30 AM SAGE Therapeutics (SAGE) Defended at Raymond James, Says Selloff is Overreaction April 20, 2018 12:05 PM Biogen (BIIB) option implied volatility elevated into Q1April 20, 2018 11:53 AM Pre-Open Movers 04/20: (LLNW) (IONS) (PF) (GE) Higher; (CLW) (SKX) (TEAM) Lower (more...)April 20, 2018 9:23 AM Biogen (BIIB) Reports $1B Payment to Ionis Pharma (IONS) for Expanded Collaboration on Neurological Diseases Drug DevelopmentApril 20, 2018 6:37 AM Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological DiseasesApril 20, 2018 6:30 AM